Congressionally Directed Medical Research Programs -- Amyotrophic Lateral Sclerosis Research Program -- Therapeutic Idea Award

Funding Agency:
Department of Defense

The Therapeutic Idea Award is designed to promote new ideas aimed at drug or treatment discovery that are still in the early stages of development. Projects that focus primarily on investigating the pathophysiology of ALS are not within the scope of this Funding Opportunity. Development and/or modification of preclinical model systems or the application of highthroughput screens to define or assess lead compounds for ALS treatment are of interest. Development of methods to adequately measure target binding and proximal downstream effects (target engagement) and the potential for undesirable activities at related but unintended targets (selectivity) are also encouraged. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative approach. All proposed research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. 

Innovation and impact are important aspects of the Therapeutic Idea Award. Research deemed innovative may introduce a new paradigm, challenge current paradigms, introduce novel concepts or technologies, or exhibit other uniquely creative qualities that may lead to potential therapeutics for ALS. Impact may be near-term or long-term, but must be significant and move beyond an incremental advancement.

The Therapeutic Idea Award encourages applications that include meaningful and productive collaborations between investigators. As appropriate, applicants are encouraged to collaborate with established ALS researchers. 

• Pre-Application Deadline: March 22, 2019
• Invitation to Submit an Application: May 2019
• Application Submission Deadline: July 25, 2019

Agency Website

Eligibility Requirements

Independent investigators at all academic levels (or equivalent) are eligible to submit applications. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.



Amount Description

The anticipated direct costs budgeted for the entire period of performance for an FY19 ALSRP Therapeutic Idea Award will not exceed $500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Funding Type



Junior Faculty
Medical Fellow/Resident
Post Doctoral Fellows


Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

March 22, 2019